Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Microneedle array-Mediated Combinatorial Photodynamic Raman Nanotheranostics for simultaneous Cancer Diagnosis and Therapy

Project description

A new light-activated approach to treating skin cancer

Skin cancer is the most common human malignancy. With disease prevalence expected to rise, there is an urgent need for more effective and accessible treatments. Photodynamic therapy, which uses light-activated molecules to destroy cancer cells, constitutes a promising alternative. However, its effectiveness is limited by poor penetration of light into skin tissue. With the support of the Marie Skłodowska-Curie Actions programme, the MNA-Cancer project proposes to develop nanoparticles that respond to X-rays instead of visible light. Dissolvable microneedles deliver these nanoparticles precisely to tumour sites, generating cancer-killing molecules deep within tissue. The approach will be tested in preclinical models with real-time monitoring, and is hoped to improve both the diagnosis and treatment of skin cancer.

Objective

Skin cancer (SC) is the most common human malignancy with rapidly increasing incidence due to numerous environmental, genetic, and metabolic reasons. Highly effective, convenient, inexpensive and widely deployable SC diagnostic and therapies are urgently needed to address this public health issue. Photodynamic Therapy (PDT) is one of the available non-invasive SC treatments that involves the combination of photosensitizer (PS), light and molecular oxygen to elicit cancer cells death by generation of reactive oxygen species (ROS). Despite its potential, PDTs effectiveness is limited by issues such as photobleaching, self-aggregation of PSs, and inadequate visible light penetration into skin tissues due to absorption by photoreceptive chromophores, necessitating further research and development.
Our proposed approach introduces a novel process using X-ray active nanotheranostic photosensitizers (NT@PS), which are developed by combining scintillators metal (e.g. Gd) with PSs (e.g. Rose Bengal) to enhance ROS production, photostability, and offer persistent luminescence properties. The outermost layer of skin limits the passive transport of PSs, therefore microneedle arrays (MNAs) technology will be used to achieve effective NT@PS delivery to deep SC sites. MNAs are an emerging drug delivery platform that addresses the limitations of conventional needle-based systems. Upon successful delivery and diffusion of NT@PS through the MNAs device, X-PDT will be assessed in-vivo using subcutaneously implanted SC cells, with real-time monitoring through Raman spectroscopy. Overall, this project aims to revolutionize skin cancer diagnosis and treatment through the development of an innovative combinatorial nanotheranostic system.
Additionally, this fellowship and mentorship from leading researcher will lay a solid foundation for the fellow independent research career, providing access to a dynamic research environment, comprehensive training and a robust collaboration network

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

THE QUEEN'S UNIVERSITY OF BELFAST
Net EU contribution
€ 276 187,92
Address
UNIVERSITY ROAD LANYON BUILDING
BT7 1NN BELFAST
United Kingdom
Region
Northern Ireland Northern Ireland Belfast
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data